28219
document
Risperidone improves behavioral symptoms in children with autism in a randomized , double-blind , placebo-controlled trial . Subgroup analysis of children ( 5-12 years ) with autism enrolled in an 8-week , double-blind , placebo-controlled trial of risperidone for pervasive developmental disorders . The primary efficacy measure was the Aberrant Behavior Checklist-Irritability ( ABC-I ) subscale . Data were available for 55 children given risperidone ( n=27 ) or placebo ( n=28 ) ; mean baseline ABC-I ( +/- SD ) was 20.6 ( 8.1 ) and 21.6 ( 10.2 ) . Risperidone [ mean dose ( +/- SD ) : 1.37 mg/day ( 0.7 ) ] resulted in significantly greater reduction from baseline to endpoint in ABC-I versus placebo [ mean change ( +/- SD ) : -13.4 ( 1.5 ) vs. -7.2 ( 1.4 ) , P < 0.05 ; ES=-0.7 ] . The most common adverse effect with risperidone was somnolence ( 74 % vs. 7 % with placebo ) . Risperidone treatment was well tolerated and significantly improved behavioral problems associated with autism .
28220
Intervention_Pharmacological
Risperidone
28221
Intervention_Control
placebo-controlled
28222
Intervention_Control
placebo-controlled
28223
Intervention_Pharmacological
risperidone
28224
Intervention_Pharmacological
risperidone
28225
Intervention_Control
placebo
28226
Intervention_Pharmacological
Risperidone
28227
Intervention_Control
placebo
28228
Intervention_Pharmacological
risperidone
28229
Intervention_Control
placebo
28230
Intervention_Pharmacological
Risperidone
28231
Outcome_Mental
behavioral symptoms
28232
Outcome_Mental
Aberrant Behavior Checklist-Irritability ( ABC-I ) subscale
28233
Outcome_Mental
ABC-I
28234
Outcome_Mental
somnolence
28235
Outcome_Other
tolerated
28236
Outcome_Mental
behavioral problems
28237
Participant_Sex
children
28238
Participant_Condition
autism
28239
Participant_Age
children ( 5-12 years )
28240
Participant_Condition
autism
28241
Participant_Sample-size
55